GlaukosGlaukos (NYSE:GKOS) announced today that it completed enrollment for a Phase 3 clinical program for its iDose TR sustained-release travoprost implant.

San Clemente, Calif.-based Glaukos’ iDose TR implant contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP) through a design that continuously releases therapeutic levels of the medication for at least one year. Once all travoprost is released, the implant can be removed and replaced with a new iDose TR as an alternative to daily eye drop treatment.

Get the full story at our sister site, Drug Delivery Business News.